Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Havel JJ, Chowell D, Chan TA.

Nat Rev Cancer. 2019 Mar;19(3):133-150. doi: 10.1038/s41568-019-0116-x. Review.

PMID:
30755690
2.

ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis.

Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP.

Cancer Immunol Res. 2018 Feb;6(2):151-162. doi: 10.1158/2326-6066.CIR-17-0114. Epub 2017 Dec 20.

3.

Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions.

Dalin MG, Katabi N, Persson M, Lee KW, Makarov V, Desrichard A, Walsh LA, West L, Nadeem Z, Ramaswami D, Havel JJ, Kuo F, Chadalavada K, Nanjangud GJ, Ganly I, Riaz N, Ho AL, Antonescu CR, Ghossein R, Stenman G, Chan TA, Morris LGT.

Nat Commun. 2017 Oct 30;8(1):1197. doi: 10.1038/s41467-017-01178-z.

4.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

5.

PRAS40 promotes NF-κB transcriptional activity through association with p65.

Zhu G, Qi Q, Havel JJ, Li Z, Du Y, Zhang X, Fu H.

Oncogenesis. 2017 Sep 25;6(9):e381. doi: 10.1038/oncsis.2017.80.

6.

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.

Riaz N, Havel JJ, Kendall SM, Makarov V, Walsh LA, Desrichard A, Weinhold N, Chan TA.

Nat Genet. 2016 Nov;48(11):1327-1329. doi: 10.1038/ng.3677. Epub 2016 Sep 26.

7.

The head and neck cancer immune landscape and its immunotherapeutic implications.

Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG.

JCI Insight. 2016 Oct 20;1(17):e89829. doi: 10.1172/jci.insight.89829.

8.

The role of neoantigens in response to immune checkpoint blockade.

Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA.

Int Immunol. 2016 Aug;28(8):411-9. doi: 10.1093/intimm/dxw019. Epub 2016 Apr 5. Review.

9.

Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform.

Mo XL, Luo Y, Ivanov AA, Su R, Havel JJ, Li Z, Khuri FR, Du Y, Fu H.

J Mol Cell Biol. 2016 Jun;8(3):271-81. doi: 10.1093/jmcb/mjv064. Epub 2015 Nov 16.

10.

High-resolution genomic analysis: the tumor-immune interface comes into focus.

Havel JJ, Chan TA.

Genome Biol. 2015 Mar 31;16:65. doi: 10.1186/s13059-015-0631-3.

11.

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA.

Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.

12.

Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway.

Havel JJ, Li Z, Cheng D, Peng J, Fu H.

Oncogene. 2015 Mar 19;34(12):1487-98. doi: 10.1038/onc.2014.91. Epub 2014 Apr 7.

13.

Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats.

Arkin MR, Glicksman MA, Fu H, Havel JJ, Du Y.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 Mar 18 [updated 2012 Oct 1].

14.

Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.

Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, Nomura T, Chung LW.

Clin Cancer Res. 2008 Sep 1;14(17):5341-7. doi: 10.1158/1078-0432.CCR-08-0793.

Supplemental Content

Loading ...
Support Center